Submission declined on 16 May 2024 by Grabup (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
| ![]() |
Submission declined on 10 May 2024 by Samoht27 (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by Samoht27 4 months ago.
| ![]() |
Submission declined on 29 December 2023 by Timtrent (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by Timtrent 8 months ago.
| ![]() |
Submission declined on 9 December 2023 by ToadetteEdit (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by ToadetteEdit 9 months ago.
| ![]() |
Submission declined on 1 December 2023 by Stuartyeates (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by Stuartyeates 9 months ago.
| ![]() |
Comment: To establish notability it needs multiple reliable independent sources with in-depth coverage of the subject not just passing mentions or interviews, sayings of the company, or connected person of the subject. GrabUp - Talk 17:12, 16 May 2024 (UTC)
Comment: Appears to not be an improvement. Toadette (Happy holiday!) 06:05, 9 December 2023 (UTC)
Comment: Press releases, patents and article by staffers are not independent. Stuartyeates (talk) 19:02, 1 December 2023 (UTC)
Nutcracker Therapeutics is a biotechnology company based in Emeryville, CA that develops mRNA-based oncology therapeutics using a proprietary microfluidics-based manufacturing technology.[1] The company was founded in 2018 by Igor Khandros, Ph.D., and Benjamin Eldridge. Khandros currently serves as chief executive officer, with Eldridge as chief technology officer.
NTX-250, Nutcracker’s lead candidate, is a multimodal RNA therapeutic primarily for use against the HPV-driven cervical cancer precursor, cervical intraepithelial neoplasia[2]. As of 2023, NTX-250 is in the preclinical stage of development.
References
edit- ^ Sheridan, Cormac (2022-08-01). "mRNA printers kick-start personalized medicines for all". Nature Biotechnology. 40 (8): 1160–1162. doi:10.1038/s41587-022-01430-y. ISSN 1546-1696. PMC 9362478. PMID 35945442.
- ^ Gormley, Brian (2023-04-26). "RNA Medicines Startup Orbital Therapeutics Collects $270 Million". Wall Street Journal. ISSN 0099-9660. Retrieved 2023-12-11.
- in-depth (not just brief mentions about the subject or routine announcements)
- reliable
- secondary
- strictly independent of the subject
Make sure you add references that meet all four of these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.